EMV CAPITAL PLC - Virtual Meet the Portfolio - AMR Bio and ProAxsis

EMV Capital PLC’s latest investor update showcases the progress of two high-potential life sciences portfolio companies, AMR Bio and ProAxsis, highlighting the group’s venture-building strategy and long-term value creation model. EMV Capital has expanded assets under management to £112 million across more than 70 portfolio companies, with a focus on scaling innovative deep-tech and healthcare businesses through strategic investment, operational support and capital syndication. AMR Bio demonstrated strong momentum with its lead antimicrobial candidate XF-73, which has delivered highly positive Phase 2b clinical results, received key FDA Fast Track and regulatory designations, and is progressing towards Phase 3 development, targeting the significant global surgical infection prevention market. Meanwhile, ProAxsis continues to build commercial traction through its proprietary protease biomarker technology, expanding recurring revenue across pharmaceutical, biotech and clinical research customers while targeting future growth in respiratory diagnostics, point-of-care testing and broader disease applications. Supported by experienced management teams, expanding commercial partnerships and clear routes to value realisation, EMV Capital remains focused on accelerating portfolio growth, driving revenue generation and delivering long-term shareholder returns through strategic exits and continued investment in high-growth life sciences innovation.